Details of the Drug

General Information of Drug (ID: DMOAD2Y)

• Drug Name: Dupilumab
• Synonyms: REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis

Indication

Disease Entry	ICD 11	Status	REF
Atopic dermatitis	EA80	Approved	[1]
Asthma	CA23	Phase 3	[2]

• Affected Organisms: Humans and other mammals
• ATC Code:
  D11AH05: Dupilumab
  D11AH: Agents for dermatitis, excluding corticosteroids
  D11A: OTHER DERMATOLOGICAL PREPARATIONS
  D11: OTHER DERMATOLOGICAL PREPARATIONS
  D: DERMATOLOGICALS
• Drug Type: Antibody
• Sequence:
  >heavy chain
  EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYY
  ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTT
  VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA
  VLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
  GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQ
  FNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ
  EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKS
  RWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
  >light chain
  DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRA
  SGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIKRTVAAPSV
  FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL
  SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 41.8 +/- 12.4 mg/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3-7 days [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 4.8 - 7 days [4]
  Metabolism: The drug is metabolized via the hepatic [4]
  Vd: The volume of distribution (Vd) of drug is 4.8 +/- 1.3 L [5]
• Cross-matching ID:
  UNII: 420K487FSG
  DrugBank ID: DB12159
  TTD ID: D07FUP
• Drug-Molecule Activity Atlas (DMA)NEW: Click to Jump to the Detailed DMA Information of This Drug
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 4 receptor alpha (IL4R)	TTDWHC3	IL4RA_HUMAN	Not Available	[6]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 14 Disease of the skin
• Disease Class: ICD-11: EA90 Psoriasis
• The Studied Tissue: Skin
• The Studied Disease: Atopic dermatitis [ICD-11:EA90]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin 4 receptor alpha (IL4R)	DTT	IL4R	1.48E-08	0.76	3.74

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Dupilumab (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Dupilumab and Siponimod.	Multiple sclerosis [8A40]	[7]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Dupilumab and Ozanimod.	Multiple sclerosis [8A40]	[8]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7574).
• [3] FDA Approved Drug Products: Dupixent (dupilumab) for subcutaneous injection
• [4] Dupixent, INN-dupilumab - European Medicines Agency - Europa EU
• [5] D'Ippolito D, Pisano M: Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. P T. 2018 Sep;43(9):532-535.
• [6] Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.
• [7] Cerner Multum, Inc. "Australian Product Information.".
• [8] Cerner Multum, Inc. "UK Summary of Product Characteristics.".